According to filings with the U.S. Securities and Exchange Commission, Elektrofi is raising up to $112,250,024.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Chase Coffman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Elektrofi
Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentration microparticle technology platform, Hypercon, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are headquartered in Boston and innovate globally. Formulating the Future of Biologics.

To learn more about Elektrofi, visit http://www.elektrofi.com/
Elektrofi Linkedin Page: https://www.linkedin.com/company/elektrofi/

Contact:
Chase Coffman, Chief Executive Officer
866-610-2683
https://www.linkedin.com/in/chase-coffman-65772b41/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.